^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Microbiome modulator

    Related drugs:
    1d
    MIYAIRI 588: CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Feb 2027 | Trial primary completion date: Mar 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Cdactin-O (CBM588)
    5d
    IMMUNOLIFE2: Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=162, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • MaaT033 • Navelbine oral (vinorelbine tartrate oral)
    20d
    The Effects of a 6-week Pre-operative Administration of a Microbiome Modulator "WellBiome" Versus Placebo on Cardiac Surgical Outcomes and NHS Cost Savings. (clinicaltrials.gov)
    P=N/A, N=80, Not yet recruiting, Hull University Teaching Hospitals NHS Trust
    New trial • HEOR
    22d
    SYN-004 Safety and Tolerability in Allo-HCT Subjects (clinicaltrials.gov)
    P1/2, N=36, Active, not recruiting, Theriva Biologics, Inc. | Trial completion date: Dec 2026 --> Sep 2030 | Trial primary completion date: Dec 2025 --> Sep 2029
    Trial completion date • Trial primary completion date
    29d
    NUTRIBRAIN: Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice (POWER) (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, National Science and Technology Council, Taiwan
    New trial
    1m
    Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis (clinicaltrials.gov)
    P2, N=58, Recruiting, The University of Texas Health Science Center, Houston | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    2ms
    PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum) (clinicaltrials.gov)
    P=N/A, N=158, Not yet recruiting, Casa di Cura Dott. Pederzoli
    New trial
    |
    Cdactin-O (CBM588)
    2ms
    COMPOSER-1: A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis (clinicaltrials.gov)
    P1, N=29, Completed, Microbiotica Ltd | Active, not recruiting --> Completed
    Trial completion
    2ms
    MET4-IO: Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients (clinicaltrials.gov)
    P2/3, N=65, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    2ms
    R-3750-01-LU: A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Rise Therapeutics LLC | Trial completion date: Dec 2027 --> Dec 2028 | Initiation date: Nov 2025 --> Sep 2026 | Trial primary completion date: Apr 2027 --> Apr 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    2ms
    R-3750 in Patients With Mild to Moderate Ulcerative Colitis (clinicaltrials.gov)
    P1, N=36, Recruiting, Rise Therapeutics LLC | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    2ms
    ROAR: REBYOTA™ Prospective Registry (clinicaltrials.gov)
    P=N/A, N=145, Completed, Ferring Pharmaceuticals | Recruiting --> Completed | Trial completion date: Apr 2026 --> Aug 2025 | Trial primary completion date: Feb 2026 --> Aug 2025
    Trial completion • Trial completion date • Trial primary completion date